Iovance Biotherapeutics, Inc. IOVA D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.2%

Gilead SciencesGILD

$98M+5.4%

ImmunityBio, Inc.IBRX

$4.38M+14.4%

Cullinan Therapeutics, Inc.CGEM

$79K+2.6%

Artiva Biotherapeutics, Inc.ARTV

$692K+8.0%

IncyteINCY

$26.48M+15.5%

FAQ

What is Iovance Biotherapeutics, Inc.'s D&A?

Iovance Biotherapeutics, Inc. (IOVA) reported D&A of $3.78M in Q2 2026.

How has Iovance Biotherapeutics, Inc.'s D&A changed year-over-year?

Iovance Biotherapeutics, Inc.'s D&A increased by 11.3% year-over-year, from $3.4M to $3.78M.

What is the long-term trend for Iovance Biotherapeutics, Inc.'s D&A?

Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s D&A has grown at a 42.6% compound annual growth rate (CAGR), from $3.11M to $12.88M.

What does D&A mean?

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.